What is HC Wainwright’s Estimate for ARTV FY2025 Earnings?

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Artiva Biotherapeutics in a research note issued on Wednesday, November 12th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($3.50) per share for the year, up from their prior forecast of ($3.55). HC Wainwright currently has a “Buy” rating and a $15.00 price target on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.95) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q4 2025 earnings at ($0.91) EPS, Q1 2026 earnings at ($0.96) EPS, Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.10) EPS, Q4 2026 earnings at ($1.16) EPS, FY2026 earnings at ($4.26) EPS, FY2027 earnings at ($1.76) EPS, FY2028 earnings at ($1.14) EPS and FY2029 earnings at ($0.74) EPS.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04.

Several other brokerages also recently commented on ARTV. Wedbush upped their target price on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an “outperform” rating in a research note on Friday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Thursday, October 30th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research note on Friday, October 17th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $19.00.

Artiva Biotherapeutics Price Performance

Shares of ARTV stock opened at $3.89 on Monday. The stock has a market cap of $95.50 million, a PE ratio of -1.51 and a beta of 3.06. The stock has a 50-day moving average of $3.40 and a 200-day moving average of $2.71. Artiva Biotherapeutics has a one year low of $1.47 and a one year high of $13.19.

Institutional Trading of Artiva Biotherapeutics

A number of institutional investors have recently modified their holdings of ARTV. Bank of America Corp DE grew its stake in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Artiva Biotherapeutics by 26.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company’s stock worth $165,000 after purchasing an additional 11,355 shares during the last quarter. Prelude Capital Management LLC bought a new position in Artiva Biotherapeutics in the third quarter valued at $41,000. Ground Swell Capital LLC acquired a new stake in Artiva Biotherapeutics in the 2nd quarter valued at $38,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in Artiva Biotherapeutics during the 2nd quarter worth about $48,000.

Insider Buying and Selling

In related news, CEO Fred Aslan sold 25,500 shares of the company’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $6.00, for a total value of $153,000.00. Following the completion of the transaction, the chief executive officer directly owned 356,721 shares of the company’s stock, valued at approximately $2,140,326. This represents a 6.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 21.40% of the company’s stock.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.